Vascular Dementia Treatment Market

Vascular Dementia Treatment Market snapshot (2023 to 2033)

Valued at USD 4.65 billion in 2022, the market for vascular dementia treatment is foreseen to rise to USD 5.64 billion in FY 2023, representing a Y-o-Y increase of over 5%. Across the forecast period ranging from 2023 to 2033, the industry is likely to gain traction at a CAGR of 4.77%, reaching a market value of USD 8.99 billion in FY 2033.

In vascular dementia, these symptoms occur when the brain is damaged because of problems with the blood supply to the brain affecting brain regions important for memory, cognition, and behavior. It declines in thinking skills, caused by conditions that block or reduce blood flow to various brain regions, depriving them of oxygen and nutrients. Cognition and brain function can be significantly affected by the size, location, and number of vascular changes. A growing number of experts prefer the term “vascular cognitive impairment” (VCI) to “vascular dementia” because they feel it better expresses the concept that vascular thinking changes can range from mild to severe. According to the Vascular Impairment of Cognition Classification Consensus Study (VICCCS) guideline, VaD can be classified into four major subtypes: post-stroke dementia (PSD) defined as dementia manifesting within 6 months after a stroke; Subcortical ischemic vascular dementia (SIVAD); Multi-infarct (cortical) dementia; and mixed dementia.

The diagnosis of vascular dementia should be suspected in patients with significant vascular risk factors, stroke, or heart disease who exhibit abrupt changes in cognition. Brain imaging demonstrating the presence of relevant lesions of cerebrovascular disease is crucial for diagnosing vascular dementia.

Data Points	Key Statistics
Documented Market Value for Vascular Dementia Treatment in 2022	USD 4.65 billion
Expected Market Value for Vascular dementia Treatment in 2023	USD 5.64 billion
Expected Market Value for vascular dementia Treatment in 2033	USD 8.99 billion
Growth rate	4.77%
Forecast period	2023 to 2033

Vascular Dementia Treatment Historical Analysis 2018 to 2022 vs. Future Prospects 2023 to 2033

According to Future Market Insights, nearly two decades of research have shown that hypertension increases the risk of AD and AD pathology. In general, data from observational epidemiology studies on hypertension and dementia are most positive but inconsistent.

Also, research surrounding the novel associations between arterial stiffness and brain Aβ deposition has considerable growth potential, and aspects relating to these two complex multifactorial pathologies need to be evaluated through more detailed studies in the future.

There is considerable room for the treatment of hypertension and arterial stiffness in the prevention of AD and dementia. Future research will also need more comprehensive assessments of cerebrovascular disease beyond white matter lesions, such as cerebral microbleeds and microinfarcts, which are cerebrovascular markers more closely related to Aβ pathology in the brain.

Prominent Drivers Influencing Market Growth of Vascular Dementia Treatment

In Vascular dementia, decreased blood flow damages the brain tissue. Blood flow to brain tissue may be reduced by a partial blockage or completely blocked by a blood clot. Currently, there is no cure for the condition or a way to reverse the damage already happened. But, treatment can help prevent further damage to the brain in people with vascular dementia and may slow down its progression.

The progress in the understanding of vascular cognitive impairment (VCI) and vascular dementia (VaD) has resulted in the development of promising symptomatic and preventive treatments. The primary prevention of treatment aims to reduce the symptoms of the disease by eliminating its cause or main risk factors. This can be achieved by addressing vascular risk factors, including arterial hypertension, lipid abnormalities, atrial fibrillation, myocardial infarction, coronary heart disease, diabetes, atherosclerosis, smoking, and hyperhomocysteinemia.

Secondary prevention may include management of stroke and prevention, by early diagnosis and appropriate treatment of acute stroke; prevention of stroke recurrence; and slowing of progression of brain changes associated with VaD by intensive management of existing risk factors.

The treatment goal includes symptomatic improvement of the core symptoms such as cognition, function, and behavior; slowing of progression of disease; and treatment of neuropsychiatric symptoms such as depression, anxiety, and others.

Region-wise Analysis

How will Vascular Dementia Treatment Assume Shape in North America?

North America is expected to occupy a major share of the overall dementia drugs market during the forecasted period. This domination is owing to the rising patient population in the region. Moreover, the rise in the number of drug approvals granted to the key manufacturers as a treatment for dementia in the region, increasing government initiative and funding to various drug development projects associated with dementia, and the rise in the number of mergers, acquisitions, and collaborations amongst dementia drug manufacturers in the region, among others are expected to drive the regional dementia drugs market in the forthcoming years.

The rise in the aging population in the United States will also propel the dementia drugs market as the aged population is more prone to developing dementia. For instance, according to the data provided by the Alzheimer’s Association, 2022, the number of Americans aged 65 years or older can be projected to grow from 58 million in the year 2021 to 88 million by the year 2050. Furthermore, several dementia-associated drugs have received an expedited approval grant from the Food and Drug Administration (FDA), causing an increase in the demand for dementia drugs, and leading to an overall increase in the dementia drugs market. For instance, on June 24, 2021, Lilly's donanemab received the United States FDA Breakthrough Therapy Designation for the treatment of Alzheimer's disease.

Thus, the interplay of all the above-mentioned factors is likely to propel the genomic market growth in the region during the forecasted period.

The situation of Vascular Dementia in the Asia-Pacific region

The increased prevalence of dementia will undoubtedly place an additional burden on healthcare services. This combines with the fact that dementia is widely considered one of the leading causes of disability in older people, and the condition is associated with social and economic complexities. Globally, most countries have established dementia care strategies but with varying priorities ranging from emphasis on early diagnosis to high-quality end-of-life care. Moreover, it was also reported that challenges in dealing with dementia in Asia include limited awareness of the disease itself, the existence of stigma, underutilization of services, urbanization, and migration, and credibility of healthcare professionals.

The latest statistics released by the Department of Statistics, in Malaysia have shown that the percentage of the population aged 65 years and over (old age) increased from 6.7% in 2019 to 7.0% in 2020; which shows that the proportion of the older age population in Malaysia has been increasing each year and is leading Malaysia to an aging nation. In addition, it is also estimated that in the year 2030, the older population will reach 15%, making Malaysia an aged nation. Therefore, Malaysia is currently in a position that requires urgent action in preparation for the increase in the number of older adults shortly.

A report by Access Economics Pty Limited for the Asia Pacific members. In 2017, the WHO convened to adopt the Global action plan on the public health response to dementia 2017 to 2025 among all member states at the 70th World Health Assembly. This action plan shall be following 10 years of advocacy for a global response to dementia. and it aims to improve the lives of people with dementia, their families, and the people who care for them while decreasing the impact of dementia on communities and countries.

Category-wise Insights

Which Type of Vascular Dementia Treatment is Most Prevalent?

According to FMI, this section focuses on the rate of uptake of the potential drugs recently launched in the Vascular Dementia (VaD) market or expected to get launched in the market during the study period 2019 to 2032. The analysis covers the Vascular Dementia (VaD) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, mergers, licensing, and patent details for Vascular Dementia (VaD) emerging therapies.

Reimbursement Scenario in Vascular Dementia (VaD)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

• Multi-infarct dementia: “Multi” means many, and “infarct” means stroke, so multi-infarct means many strokes that affect blood flow to multiple areas of your brain. Changes from these strokes are often noticeable when they happen, and so cognitive changes occur in a step-wise fashion (sudden worsening over multiple periods).
• Binswanger disease: This is a term for vascular dementia that happens when small blood vessels located throughout white matter (deep areas of your brain containing the “wiring” or connections between brain areas) are blocked over time by atherosclerosis (“hardening of the arteries”). This type of dementia, also called subcortical vascular dementia, occurs gradually over time (without sudden episodes of worsening).
• Vascular dementia from a strategic single-infarct: Vascular dementia can occur after only one stroke if the blockage destroys brain tissue that’s needed for more than one thinking ability.

BAC: Charsire Biotechnology Corp

BAC (also called CSTC1, CHARSIRE Trauma Complex 1), a component of soybean extraction developed by Charsire Biotechnology Corp, is under investigation to treat a variety of diseases, including AD and VaD. BAC is a vapor fraction from seeds of Glycine max (L.) Merr. BAC in its studies showed to promote the proliferation of neuroblastoma IMR-32 cells, and this observation may correlate to the improvement of the cognitive performance in the heavy metal-induced AD mice and the VaD-resembled rats when treated with BAC.

PNA1: ProNeurogen Therapeutics

PNA1, a rationally-designed Angiotensin-(1-7) Mas receptor agonist that has enhanced BBB penetration half-life and is designed to inhibit chronic inflammatory pathways in both the brain and the cerebrovasculature endothelium. These pathways are involved in vascular dementia and neuropathic pain. These novel peptide formulations are designed to act on Mas receptors (MasR) within the brain vascular endothelium and neuronal cells and microglia to decrease brain ROS production and neuroinflammation. The drug candidate is based on technology developed at the University of Arizona.

Competitive Landscape

Some of the prominent players are-

• Charsire Biotechnology Corp
• ProNeurogen Therapeutics
• Resverlogix Corp.
• Eisai Co., Ltd.
• Novartis AG
• Cipla Inc.
• Aurobindo Pharma
• Sun Pharmaceutical Industries Ltd
• Dr. Reddy’s Laboratories Ltd
• Johnson & Johnson Services, Inc.

Report Scope

Report Attribute	Details
Growth Rate	4.77%
Market Value in 2023	USD 5.64 billion
Market Value in 2033	USD 8.99 billion
Base Year for Estimation	USD 4.65 billion
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Type, Treatment, End User, Region
Regions Covered	North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East and Africa
Key Countries Profiled	United States, Canada, Brazil, Mexico, Rest of Latin America, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, India, Malaysia, Singapore, Thailand, Australia, New Zealand, GCC Countries, South Africa, Israel
Key Companies Profiled	BCG Matrix; PESTLE Analysis; SWOT Analysis; Porter’s five forces; Market Entry Strategies, Inc.; Eisai Inc.; Ever Neuro Pharma GmbH; Geny Research Corp.; Novartis; Charsire Biotechnology Corp.; LLC Merz Pharma; Otsuka Pharmaceutical Co. Ltd.; Johnson & Johnson Pharmaceutical Research & Development LLC.
Report Customization & Pricing	Available upon Request

Key Segments Profiled in the Vascular Dementia Treatment Industry Analysis

By Type:

• Pipeline Development Activities
• Reimbursement Scenario in Vascular Dementia (VaD)
• Multi-infarct dementia
• Binswanger disease
• Vascular dementia from a strategic single-infarct
• BAC: Charsire Biotechnology Corp
• PNA1: ProNeurogen Therapeutics

By Treatment:

• Drug class
• Route of administration
• Distribution channel

By End User:

• Hospitals and Clinics
• Rehabilitation Centers
• Others

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

Frequently Asked Questions

What is the Vascular Dementia Treatment Market value in 2023?

In 2023, the market is valued at USD 5.64 billion.

What will be the growth rate until 2033?

Until 2033, the market will experience a 4.77% CAGR.

What is majorly propelling the market growth?

The rising patient population drives market growth.

What is the market value for 2033?

The market is expected to be valued at USD 8.99 billion by 2033.

Who are key Vascular Dementia Treatment Market players?

Charsire Biotechnology Corp, ProNeurogen Therapeutics, and Resverlogix Corp. are some key players.